Enrolling By InvitationNCT05165316

European Long-acting Antipsychotics in Schizophrenia Trial-II

Observational studyAges 18+Israel

The study in practice

Understand this study

This study is for people with schizophrenia. Listed age limits: from 18 years. Other eligibility criteria apply.

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Study start dateStarted: December 31, 2021

Recruitment status: Enrolling By Invitation
Enrollment listed in the registry: 400
Sponsor: Rene Kahn
Sponsor type: Unknown or unclear
Study type: Observational
Intervention type: Interview / survey / observational
Study phase: Not clearly listed
Locations: Israel
Age range: Over 18 Years
Official registry ID: NCT05165316
Official title: Show the full official title
European Long-acting Antipsychotics in Schizophrenia Trial-II

Leave your email and we’ll get in touch to discuss your questions and possible next steps.

By invitation

Ramat Gan

A listed location does not confirm current availability.

FAQ

Who is behind this study?

The study sponsor is Rene Kahn.

Who can participate?

This study is for people with schizophrenia. Listed age limits: from 18 years. Other eligibility criteria apply.

Is this study still recruiting?

The registry lists this study as enrolling by invitation.

Explore other studies

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.